clinical trial · NCT07222267
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
BeOne Medicines·phase1·recruiting·n = 86
Breast CancerAdvanced Solid TumorBG-75202CDK4 InhibitorEstrogen Receptor AntagonistAromatase Inhibitor
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
started
Dec 11, 2025
primary completion
Sep 30, 2029
completion
Jan 13, 2037
last updated
Apr 22, 2026
official title
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol